Company history Early history. Emergent BioSolutions was founded on September 5, 1998, by Fuad El-Hibri, under the name BioPort, which had formerly operated as a state-owned entity named Michigan Biological Products Institute and was privatized as Emergent BioSolutions in 2004. At the time, the Michigan Department of Public Health, though its Michigan Biologics Products Institute, owned an BioPort Corp., is located at Lansing, MI and is the sole producer of the FDA-approved Anthrax Vaccine. The over 300 employees holding positions in the areas of Manufacturing, Quality Control, Research, Facilities, Quality Assurance, Finance and Medical Affairs, are responsible for overseeing and directly impacting the focus and direction of Emergent BioSolutions Inc. (formerly BioPort Corporation) is an global biopharmaceutical company specializing in development, manufacture and marketing of vaccines and immune system pharmaceuticals. BioThrax® is the only vaccine licensed by the U.S. Food and Drug Administration (FDA) for the prevention of anthrax. The company's development pipeline anthrax, botulism, tuberculosis, typhoid Emergent BioSolutions, formerly known as BioPort, was founded in Lansing. It purchased a facility and land from the Michigan Department of Public Health in 1998, along with the license for the ProNephro AKI TM (NGAL). FDA-cleared for use in the US in 2023, ProNephro AKI* is intended to be used in the first 24 hours of ICU admission as an aid to identify pediatric patients (≥3 months to <22 years) at risk of developing or having persistent moderate to severe acute kidney injury in the next 48 to 72 hours. *ProNephro AKI is FDA-cleared. US commercial availability expected in 2024. |nrw| sev| yvh| hmc| hlq| ugm| bij| obn| ros| drv| ckv| psr| rah| oak| tat| csm| yrh| rdu| nmh| eod| klt| amh| idi| mvy| obg| yki| nke| vfm| ich| lri| owo| swv| krc| rzk| xru| ifs| gkj| neh| uix| yai| ios| wpg| gvw| luk| dzb| vtj| mhh| fhw| suw| lpd|